JP2024507118A5 - - Google Patents
Info
- Publication number
- JP2024507118A5 JP2024507118A5 JP2023547794A JP2023547794A JP2024507118A5 JP 2024507118 A5 JP2024507118 A5 JP 2024507118A5 JP 2023547794 A JP2023547794 A JP 2023547794A JP 2023547794 A JP2023547794 A JP 2023547794A JP 2024507118 A5 JP2024507118 A5 JP 2024507118A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- mol
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148543P | 2021-02-11 | 2021-02-11 | |
| US63/148,543 | 2021-02-11 | ||
| PCT/US2022/016229 WO2022174114A1 (en) | 2021-02-11 | 2022-02-11 | Anti-transferrin receptor fusion proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507118A JP2024507118A (ja) | 2024-02-16 |
| JP2024507118A5 true JP2024507118A5 (https=) | 2025-02-18 |
Family
ID=82837358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547794A Pending JP2024507118A (ja) | 2021-02-11 | 2022-02-11 | 抗トランスフェリン受容体融合タンパク質及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20240148866A1 (https=) |
| EP (1) | EP4291246A4 (https=) |
| JP (1) | JP2024507118A (https=) |
| CN (1) | CN116997364A (https=) |
| MA (1) | MA71665A (https=) |
| WO (1) | WO2022174114A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120265319A (zh) * | 2022-09-20 | 2025-07-04 | 丹娜-法伯癌症研究院 | 受体介导的胞吞作用用于膜蛋白和货物的靶向内化和降解 |
| EP4630455A1 (en) | 2022-12-05 | 2025-10-15 | Sanofi | Transferrin receptor binding proteins |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| DK2729482T3 (en) * | 2011-07-08 | 2018-05-07 | Merck Sharp & Dohme | PROCEDURE FOR CLEANING FC-FUSION PROTEIN |
| EP3088518A4 (en) * | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| SG11201901495YA (en) * | 2016-08-25 | 2019-03-28 | Jcr Pharmaceuticals Co Ltd | Method for producing antibody fusion protein |
| KR102497564B1 (ko) * | 2016-12-26 | 2023-02-07 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체 |
| AU2017386888B2 (en) * | 2016-12-28 | 2024-08-08 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| CR20200129A (es) * | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| US20220002688A1 (en) * | 2018-12-20 | 2022-01-06 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
-
2022
- 2022-02-11 EP EP22753465.8A patent/EP4291246A4/en active Pending
- 2022-02-11 JP JP2023547794A patent/JP2024507118A/ja active Pending
- 2022-02-11 CN CN202280022750.1A patent/CN116997364A/zh active Pending
- 2022-02-11 MA MA71665A patent/MA71665A/fr unknown
- 2022-02-11 WO PCT/US2022/016229 patent/WO2022174114A1/en not_active Ceased
- 2022-02-11 US US18/276,823 patent/US20240148866A1/en active Pending
-
2025
- 2025-08-19 US US19/304,112 patent/US20250387477A1/en active Pending
- 2025-08-19 US US19/304,134 patent/US20250367284A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7789871B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| JP2023517236A5 (https=) | ||
| KR101949891B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| JP2024507118A5 (https=) | ||
| JP6672533B1 (ja) | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 | |
| US20250109191A1 (en) | Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitor | |
| EA033359B1 (ru) | Комбинация леналидомида и полипептидной конструкции и ее применение | |
| WO2014181229A2 (en) | Anti-glucagon receptor antibodies and methods of use thereof | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| KR20180084045A (ko) | 비형 간염 표면 항원에 대한 항체 및 그의 용도 | |
| JP7809067B2 (ja) | 抗セラミド抗体 | |
| TWI808963B (zh) | 使用人類化抗ｃｘｃｒ５抗體治療狼瘡 | |
| CN120693172A (zh) | 用于治疗补体介导的疾病的与因子h融合的抗c5抗体 | |
| JP2024532426A5 (https=) | ||
| US20250134988A1 (en) | Pan-Coronavirus Immunogenic Compositions | |
| CN114127108A (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| US20220332822A1 (en) | Subcutaneous administration of antibodies for the treatment of disease | |
| WO2026072993A1 (en) | Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody | |
| CN117866092A (zh) | 抗人cd73抗体或其抗原结合片段及其应用 | |
| CN116457370A (zh) | 包含抗原和其醣工程化抗体的免疫组合物 |